Form 4: Contineum Therapeutics CSO Executes Stock Sale

Chief Scientific Officer Daniel S. Lorrain sold 4,170 shares of Contineum Therapeutics common stock via a 10b5-1 plan.

Summary

• Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, sold 4,170 shares of Class A Common Stock.
• The shares were sold at a weighted average price of $13.1564 per share.
• The transaction was executed on June 1, 2026, pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025.
• Following the transaction, the reporting person directly owns 139,372 shares and indirectly owns 10,110 shares through a spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a small portion of the executive's total holdings.

Positives

• The sale was conducted under a pre-established 10b5-1 trading plan, indicating the transaction was scheduled in advance rather than based on non-public information.

Negatives

• The sale represents a reduction in the insider's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on current valuation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for executives to manage personal liquidity and does not necessarily reflect a change in the company's fundamental outlook.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate insiders to sell shares while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact expected as the transaction was pre-planned and limited in volume.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Contineum Therapeutics, CTNM, Insider Trading, Form 4, Chief Scientific Officer, Equity Sale